- The share
- Press releases
- Financial calendar
- Financial reports
- Prospectus and material offerings
- Financial presentations
- Corporate governance
- Analyst Coverage
- Code of Conduct
- Contact us
- Thank you
XVIVO Perfusion extends the acceptance period for the public offer on Vivoline Medical
The Offer is not made, and this press release may not, directly nor indirectly, be distributed in or to, Australia, Hong Kong, Japan, Canada, New Zeeland, South Africa or the U.S or in any other country where making of the Offer, distribution of this press release or acceptance of the Offer would be contrary to applicable laws or rules or would require further offering documentation or registration or any other measures in addition to what is required by Swedish law.
XVIVO Perfusion AB (“XVIVO Perfusion”) announced on 18 April 2016 a recommended public offer to the holders of shares (“Shares”) and warrants of series 2015/2016 (“Warrants”) in Vivoline Medical AB (“Vivoline”) to transfer all of their Shares and Warrants to XVIVO Perfusion (the “Offer”). At the expiry of the ordinary acceptance period on 7 June 2016, 10,774,457 Shares (corresponding to 94.5 percent of the total number of Shares) and 4,132,943 Warrants (corresponding to 96.8 percent of the total number of Warrants) had been submitted in the Offer. Against this background, XVIVO Perfusion declared the Offer unconditional and extended the acceptance period until and including 20 June 2016.
During the extended acceptance period, 288,135 Shares (corresponding to 2.5 percent of the total number of Shares) and 88,327 Warrants (corresponding to 2.1 percent of the total number of Warrants) have been submitted in the Offer. Accordingly, a total of 11,062,592 Shares (corresponding to 97.0 percent of the total number of Shares) and 4,221,270 Warrants (corresponding to 98.9 percent of the total number of Warrants) have been submitted in the Offer. XVIVO Perfusion has not acquired any Shares or Warrants outside of the Offer and does not hold any Shares or Warrants or other financial instruments that entails a financial exposure which corresponds to a holding of Shares or Warrants in Vivoline. Payment of consideration to the holders of Shares and Warrants that have accepted the Offer during the extended acceptance period will begin around 23 June 2016. The board of XVIVO Perfusion has consequently resolved upon a new issue of not more than 52,082 shares in XVIVO Perfusion with payment in kind consisting of Shares and Warrants.
In order to grant the remaining holders of Shares and Warrants more time to accept the Offer, the acceptance period is being extended until and including 14 July 2016. Payment of the consideration to the holders of Shares and Warrants that accept the Offer during the extended acceptance period may be made continuously. However, the final payments of the consideration are estimated to be made around 20 July 2016.
XVIVO Perfusion reserves the right to further extend the acceptance period.
XVIVO Perfusion has initiated a compulsory redemption process of the remaining Shares and Warrants. In addition, Vivoline has on 17 June 2016 announced that the Shares and Warrants will be delisted from Nasdaq First North and that the last trading day in the Shares and Warrants will be 8 July 2018.
The information provided herein is such that XVIVO Perfusion is obligated to disclose pursuant to the Takeover Rules. The information was submitted for publication at 7.30 a.m. CET, 21 June 2016.
For further information, please contact:
Magnus Nilsson, CEO
+46 (0)31-788 21 50
Gothenburg 21 June 2016
XVIVO Perfusion AB (publ)
The Offer is not being made to persons whose participation in the Offer requires that any additional offer document or prospectus is prepared or registration effected or that any other measures are taken in addition to those required under Swedish laws and rules.
This press release and any other documentation relating to the Offer are not being distributed and must not be mailed or otherwise distributed or sent in or into any country in which distribution or offering would require any such additional measures to be taken or would be in conflict with any law or regulation in such country – XVIVO Perfusion will not allow or accept any such measure. Any purported acceptance of the Offer resulting directly or indirectly from a violation of these restrictions may be disregarded.
The Offer is not being made and will not be made, directly or indirectly, by use of mail or any other communication means or facility, either by intergovernmental nature or for foreign trade or through national stock exchanges’ facilities, in or into Australia, Hong Kong, Japan, Canada, New Zealand, South Africa or the U.S. This includes, without limitation, facsimile transmission, electronic mail, telex, telephone and the internet or other forms of electronic distribution. The Offer cannot be accepted and Shares and Warrants cannot be transferred in the Offer, by any such measures, means, instrumentality or facility of, or from within Australia, Hong Kong, Japan, Canada, New Zealand, South Africa or the U.S. or by persons that are located in, or resident in Australia, Hong Kong, Japan, Canada, New Zealand, South Africa or the U.S. Accordingly, this press release and any documentation related to the Offer are not being and should not be mailed or otherwise distributed, forwarded or sent in or into Australia, Hong Kong, Japan, Canada, New Zealand, South Africa or the U.S. or to a person that is located in, or resident in Australia, Hong Kong, Japan, Canada, New Zealand, South Africa or the U.S.
Every attempt to transfer Shares or Warrants in the Offer which, directly or indirectly, is a result of a violation of these restrictions is invalid and every attempt to transfer Shares or Warrants by a person who is located in Australia, Hong Kong, Japan, Canada, New Zealand, South Africa or the U.S. or by representatives, agents or other intermediary who acts on non-discretionary basis for a principal who delivers instructions from or within Australia, Hong Kong, Japan, Canada, New Zealand, South Africa or the U.S. is invalid and will not be accepted. Every person who holds Shares or Warrants and who participates in the Offer will certify that the person is not from, or is not located in or deliver instructions to participate in the Offer from, Australia, Hong Kong, Japan, Canada, New Zealand, South Africa or the U.S., and that they are not acting on a non-discretionary basis on behalf of a principal who is from, is located in or gives an order to participate in the Offer from Australia, Hong Kong, Japan, Canada, New Zealand, South Africa or the U.S. XVIVO Perfusion will not deliver any consideration in accordance with the Offer in or into Australia, Hong Kong, Japan, Canada, New Zealand, South Africa or the U.S.
This press release is not being, and must not be, sent to holders of Shares or Warrants with registered addresses in Australia, Hong Kong, Japan, Canada, New Zealand, South Africa or the U.S. Banks, brokers, dealers and other nominees holding Shares or Warrants for persons in Australia, Hong Kong, Japan, Canada, New Zealand, South Africa or the U.S. may not forward this press release or any other document received in connection with the Offer to such persons.
The term “U.S.” shall in this section have the meaning the United States of America, its territories and dependencies (including Puerto Rico, American Virgin Islands, Guam, American Samoa, Wake Islands and Commonwealth of the Northern Mariana Islands), every state within the United States of America and the Columbia District.
Statements in this press release relating to future status or circumstances, including statements regarding future performance, growth and other trend projections and the other benefits of the Offer, are forward-looking statements. These statements may generally, but not always, be identified by the use of words such as “anticipates”, “intends”, “expects”, “believes”, or similar expressions. By their nature, forward-looking statements involve risk and uncertainty because they relate to events and depend on circumstances that will occur in the future. There can be no assurance that actual results will not differ materially from those expressed or implied by these forward-looking statements due to many factors, many of which are outside the control of XVIVO Perfusion. All such forward-looking statements are only valid as of the day when the statements were made and XVIVO Perfusion does not have any obligations (and does not undertake any obligation) to update or audit the statements, as a consequence of new information, future occurrences or other circumstances, except as required according to law and other regulation.
For further information please contact:
Christoffer Rosenblad, CFO, +1 720 616 2101, firstname.lastname@example.org
Magnus Nilsson, CEO, +46 31 788 2150, email@example.com
For further information on XVIVO Perfusion’s business, please refer to the company’s website, www.xvivoperfusion.com
This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.